Yangbing Zhao

List of Publications by Citations

52 papers	7,321 citations	36 h-index	54 g-index
54 ext. papers	8,741 ext. citations	9.1 avg, IF	5.71 L-index

#	Paper	IF	Citations
52	Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. *Cancer Immunology Research*, **2014**, 2, 112-20	12.5	558
51	Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. *Clinical Cancer Research*, **2017**, 23, 2255-2266	12.9	495
50	CRISPR-engineered T cells in patients with refractory cancer. *Science*, **2020**, 367,	33.3	448
49	T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. *Cancer Immunology Research*, **2013**, 1, 26-31	12.5	376
48	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. *Nature*, **2018**, 558, 307-312	42.4	362
47	Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. *Cancer Research*, **2010**, 70, 9053-61	10.1	334
46	Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. *Cancer Research*, **2006**, 66, 8878-86	10.1	325
45	A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. *Cancer Research*, **2016**, 76, 1578-90	10.1	308
44	Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. *Cancer Research*, **2015**, 75, 3596-607	10.1	298
43	Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. *Journal of Immunology*, **2008**, 180, 6116-31	5.3	248
42	Dominant-Negative TGF-βReceptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. *Molecular Therapy*, **2018**, 26, 1855-1866	11.7	247
41	A versatile system for rapid multiplex genome-edited CAR T cell generation. *Oncotarget*, **2017**, 8, 17002-17011	5.3	237
40	High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. *Molecular Therapy*, **2006**, 13, 151-9	11.7	229
39	A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. *Journal of Immunology*, **2009**, 183, 5563-74	5.3	227
38	Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18. *Cell Reports*, **2017**, 20, 3025-3033	10.6	205
37	Adoptive immunotherapy for cancer or viruses. *Annual Review of Immunology*, **2014**, 32, 189-225	34.7	201
36	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. *Cancer Immunology Research*, **2017**, 5, 1152-1161	12.5	181

35	Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. *Cancer Immunology Research*, **2015**, 3, 356-67	12.5	181
34	Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. *Journal of Clinical Investigation*, **2010**, 120, 3953-68	15.9	163
33	High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. *Journal of Immunology*, **2007**, 179, 5845-54	5.3	162
32	Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. *Journal of Immunology*, **2005**, 174, 4415-23	5.3	158
31	Treatment of advanced leukemia in mice with mRNA engineered T cells. *Human Gene Therapy*, **2011**, 22, 1575-86	4.8	149
30	Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. *Journal of Immunology*, **2005**, 175, 5799-808	5.3	111
29	T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. *Cancer Immunology Research*, **2013**, 1, 26-31	12.5	94
28	Engineered T cells for cancer therapy. *Cancer Immunology, Immunotherapy*, **2014**, 63, 969-75	7.4	90
27	Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. *Clinical Cancer Research*, **2016**, 22, 436-47	12.9	84
26	Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. *Human Gene Therapy*, **2013**, 24, 717-27	4.8	84
25	Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. *Cancer Research*, **2007**, 67, 2425-9	10.1	78
24	Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. *Cytotherapy*, **2014**, 16, 619-30	4.8	74
23	Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. *Cancer Immunology, Immunotherapy*, **2009**, 58, 383-94	7.4	70
22	Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. *Protein and Cell*, **2017**, 8, 634-643	7.2	64
21	A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. *Cancer Research*, **2010**, 70, 3027-33	10.1	58
20	Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. *Human Gene Therapy*, **2009**, 20, 630-40	4.8	57
19	Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. *Cancer Immunology Research*, **2014**, 2, 1059-70	12.5	52
18	Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. *Protein and Cell*, **2017**, 8, 573-589	7.2	47

17	TCR affinity and specificity requirements for human regulatory T-cell function. *Blood*, **2012**, 119, 3420-30	2.2	37
16	Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. *Oncotarget*, **2015**, 6, 28911-28	3.3	35
15	CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy. *Current Research in Translational Medicine*, **2018**, 66, 39-42	3.7	31
14	Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. *Blood*, **2003**, 102, 4137-42	2.2	28
13	Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes. *Journal of Immunotherapy*, **2006**, 29, 398-406	5	23
12	iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. *Genome Biology*, **2019**, 20, 14	18.3	20
11	Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. *Human Gene Therapy*, **2013**, 24, 27-37	4.8	15
10	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. *Journal of Clinical Investigation*, **2021**, 131,	15.9	15
9	Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma. *Journal of Immunological Methods*, **2011**, 366, 43-51	2.5	14
8	Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against Leukemia. *Blood*, **2015**, 126, 4280-4280	2.2	12
7	Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation. *Protein and Cell*, **2017**, 8, 514-526	7.2	10
6	Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology. *Journal of Cellular and Molecular Medicine*, **2011**, 15, 327-38	5.6	10
5	First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. *Blood*, **2019**, 134, 49-49	2.2	7
4	Donor-type chimerism determination by competitive polymerase chain reaction (PCR) in a primate model for bone marrow transplantation. *Transplantation*, **1999**, 68, 1573-7	1.8	4
3	Distinct Signaling By Chimeric Antigen Receptors (CARs) Containing CD28 Signaling Domain Versus 4-1BB In Primary Human T Cells. *Blood*, **2013**, 122, 2902-2902	2.2	2
2	Improved Anti-Leukemia Activities of Adoptively Transferred T Cells Expressing Bites. *Blood*, **2015**, 126, 4431-4431	2.2	2
1	Construction and Pre-Clinical Evaluation of An Anti-CD19 Chimeric Antigen Receptor. *Blood*, **2008**, 112, 4623-4623	2.2	1